Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974294 | 1.00 | CXCR2 (0.42) | CXCR2KCNH2TLR9GBA1CNR1 | |
| SCHEMBL29409403 | 0.89 | KCNH2 (0.42) | CXCR2KCNH2TLR9GBA1CNR1 | |
| SCHEMBL29914108 | 0.89 | GBA1 (0.43) | CXCR2KCNH2TLR9GBA1CNR1 | |
| SCHEMBL24161673 | 0.89 | GBA1 (0.43) | CXCR2KCNH2TLR9GBA1CNR1 | |
| SCHEMBL16637001 | 0.89 | KCNH2 (0.42) | CXCR2KCNH2TLR9GBA1CNR1 | |
| SCHEMBL31658007 | 0.87 | TSHR (0.52) | CXCR2KCNH2TLR9GBA1CNR1 | |
| SCHEMBL30569579 | 0.87 | KCNH2 (0.42) | CXCR2KCNH2TLR9GBA1CNR1 | |
| SCHEMBL16636992 | 0.87 | KCNH2 (0.42) | CXCR2KCNH2TLR9GBA1CNR1 | |
| SCHEMBL18128414 | 0.87 | TSHR (0.52) | CXCR2KCNH2TLR9GBA1CNR1 | |
| SCHEMBL16636843 | 0.86 | TLR9 (0.42) | CXCR2KCNH2TLR9GBA1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| EP-4329888-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Amgen Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117651700-A | 2-aminobenzothiazole compounds and methods of use | 安进公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117500799-A | Substituted fused azines as KRAS G12D inhibitors | 伊莱利利公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022261154-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | CXCR2 489/4885KCNH2 1048/4885TLR9 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.